Results 131 to 140 of about 9,498 (160)

Sofosbuvir

Reactions Weekly, 2023
openaire   +1 more source

Ledipasvir/sofosbuvir/sofosbuvir

Reactions Weekly, 2018
openaire   +1 more source

Daclatasvir/sofosbuvir/ledipasvir/sofosbuvir

Reactions Weekly, 2019
openaire   +1 more source

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

New England Journal of Medicine, 2013
Eric Lawitz, Alessandra Mangia, K Rajender Reddy   +2 more
exaly   +2 more sources

Sofosbuvir + simeprevir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2014
openaire   +1 more source

Ledipasvir/sofosbuvir/peginterferon/ribavirin/sofosbuvir

Reactions Weekly, 2016
openaire   +1 more source

Daclatasvir + sofosbuvir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2017
openaire   +1 more source

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Zobair M Younossi   +2 more
exaly  

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

Lancet, The, 2013
Kris V Kowdley, Eric Lawitz, Nezam Afdhal   +2 more
exaly  

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Lancet, The, 2014
Eric Lawitz
exaly